The Massachusetts Institute of Technology’s Center for Biomedical Innovation hosts a 2–day Summit on Cell and Gene Therapy biomanufacturing.

The 2015 BioMAN Summit will bring together thought leaders from industry, academia and government for a series of invited presentations and panel discussions that will:

• Explore the manufacturing challenges of cell and gene therapy products;
• Examine the science and enabling technology for product safety;
• Discuss the critical needs for sustainable commercial manufacturing.

A Poster Session highlighting cell and gene therapy related research will take place. Prizes sponsored by CASSS – An International Separation Science Society.

Gary C. du Moulin, Associate Professor, Massachusetts College of Pharmacy and Health Sciences University

Denise Gavin, Acting Gene Therapy Branch Chief, Gene Therapy Branch, Division of Cell and Gene Therapy,
Center for Biologics Evaluation and Research, US FDA

Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania

David Williams, Professor of Healthcare Engineering, University Academic Research Challenge Lead - Health and Wellbeing, Loughborough University

Myriam Armant, Director, TransLab, Boston Children’s Hospital

Dominic Clarke, Global Product Manager, Cell Therapy & Bioprocessing, Charter Medical

John Duguid, Director, Process Development, Vericel

Brian Hawkins, Senior Application Scientist, BioLife Solutions

Eileen Higham, Product Development Team Leader, MedImmune

Joseph Hughes, Vice President, Technology Development and Chief Scientist, WuXi AppTec

Rosemarie Hunziker, Program Director, Tissue Engineering/Regenerative Medicine,
Biomaterials and Implantable Medical Devices, NIH / NIBIB

Sadik Kassim, Associate Director, Cell & Gene Therapies Unit, Novartis

Steve Kennedy, Chief Technology Officer, Histogenics

Bill Lundberg, Chief Scientific Officer, CRISPR Therapeutics

Mark McCall, Lecturer, Loughborough University

Knut Niss, CMC Team Director, Pharmaceuticals Operations & Technology, Biogen

Michael Paglia, Senior Director, Technical Operations, bluebirdbio

Anne Plant, Division Chief, Biosystems and Biomaterials, NIST

Jerome Ritz, Executive Director, Connell O’Reilly Cell Manipulation Core Facility, Dana-Farber Cancer Institute,
Brigham and Women’s Hospital

Martha Rook, Director, Stem Cell Bioprocessing Group, EMD Millipore

Jamie Thurman-Newell, Principal Investigator – Healthcare Technologies Group, Loughborough University

Michael Washabaugh, Senior Director, MedImmune

Alison Wilson, Principal Consultant, Cell Data Services

J. Fraser Wright, Co-Founder and Chief Technology Officer, Spark Therapeutics